Non-intentional weight loss of >10% over six months. General physical decline. Serum albumin <25g/L. Dependence in most activities of daily living. This position statement does not cover the specific modalities of death that occur with an increased

frequency in those with diabetes because, by definition, they cannot be anticipated and therefore an EOLC strategy is not appropriate. However, knowledge of their existence may help those dealing with the bereaved in the aftermath of RG7420 datasheet the death of a patient with diabetes. Both ‘Dead in Bed’ syndrome and sudden in-utero fetal death, although rare, are more common in people with diabetes; the exact aetiology in both cases has yet to be established. As the population of the UK ages and the incidence of diabetes rises, more individuals will be reaching the end of their life with co-existent diabetes. In the words of Prof J Saunders, diabetologist and ethicist: ‘Dying patients should receive care that offers comfort, dignity and freedom from distressing symptoms as far as these are possible.’ That includes those with diabetes for whom the aim should be to keep the blood glucose within

a range http://www.selleckchem.com/products/PD-0332991.html which will avoid symptoms while reducing invasive tests, such as blood glucose monitoring, to a minimum. This position statement offers some guidance for the management of diabetes during the end stages of life and hopes to trigger discussion within the multidisciplinary diabetes teams relating to their role in EOLC. The MDT should engage with user groups and primary and secondary care colleagues to enhance the provision of end of life care for patients with diabetes for whom we are both carers and advocates. There are no conflicts of interest. Readers can go to the following websites and retrieve information on end of life care in diabetes: www.diabetes.org.uk. www.diabetes.nhs.uk/commissioning. End

of Life Care Strategy – promoting high quality care for all adults at the end of life. Department of Health, July 2008. Marks JB. Addressing end-of-life issues. Clin second Diabetes 2005; 23(3): 98–9. Vandenhaute V. Palliative care and type II diabetes: A need for new guidelines? Am J Hosp Palliat Care 2010; 27(7): 444–5. Epub 2010 Apr 13. “
“We aimed to assess the utility and acceptability of outpatient glucose self-monitoring in an adult cystic fibrosis (CF) population. Adults with CF were asked to self-monitor their capillary glucose, three times per day for two weeks preceding their hospital outpatient appointment. The American Diabetes Association definition of dysglycaemia was used, defined by at least two elevated glucose recordings of fasting glucose ≥5.6mmol/L or post-prandial glucose ≥7.8mmol/L. From a CF population of 43 patients, 10 were excluded (mainly due to clinic in-attendance). Of the remaining 33 patients, 29 (88%) consented to perform glucose self-monitoring, and 22 patients (67% of eligible patients and 76% of those consenting to take part) provided glucose data.